Background Oxidative stress and smoking contribute to endothelial dysfunction. Iron might also play a role in oxidative stress generation and endothelial dysfunction. However, the involvement of iron in smoking-induced endothelial dysfunction in healthy smokers remains unclear. Therefore, we examined here whether (1) intravenous iron infusion impaired endothelial function evaluated by flow-mediated vasodilatation (FMD) in non-smokers, and (2) deferoxamine, a potent iron chelator, ameliorated endothelial dysfunction in healthy smokers. Methods Eight healthy young male non-smokers (23±4 years old) received intravenous injection of saccharated ferric oxide (0.7 mg/kg body weight), while 10 age-matched healthy male smokers received deferoxamine mesylate (8.3 mg/kg body weight). At baseline, 5 and 20 minutes after treatment with iron or deferoxamine, biochemical variables were measured, including serum iron and marondialdehyde (MDA), a marker of lipid oxidation, and endothelial function was simultaneously evaluated by FMD. Results Compared with non-smokers, FMD was significantly lower in smokers. Iron and MDA levels were significantly increased, whereas FMD was impaired by iron infusion in non-smokers. Conversely, deferoxamine treatment significantly decreased iron and MDA levels and restored the decreased FMD in smokers. Baseline serum iron and MDA levels in all 18 subjects (non-smokers and smokers) were correlated with each other. There was a significant inverse correlation between the changes in MDA values and FMD from baseline in 18 men. Endothelium-independent vasodilation by glyceryl trinitrate was unaltered by either treatment. Conclusions Our present study suggests that iron-evoked oxidative stress might play a role in endothelial dysfunction in healthy smokers.
References
[1]
Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27–32. doi: 10.1161/01.cir.0000131515.03336.f8
[2]
Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115: 1285–1295.
[3]
Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S (2008) Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des 14: 2613–2618. doi: 10.2174/138161208786071326
[4]
Fratta Pasini A, Albiero A, Stranieri C, Cominacini M, Pasini A, et al. (2012) Serum oxidative stress-induced repression of Nrf2 and GSH depletion: a mechanism potentially involved in endothelial dysfunction of young smokers. PLoS One 7: e30291. doi: 10.1371/journal.pone.0030291
[5]
Stirban A, Nandrean S, Kirana S, G？tting C, Veresiu IA, et al. (2012) Benfotiamine counteracts smoking-induced vascular dysfunction in healthy smokers. Int J Vasc Med 2012: 968761. doi: 10.1155/2012/968761
[6]
Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840–844. doi: 10.1161/01.res.87.10.840
[7]
Ando R, Ueda S, Yamagishi S, Miyazaki H, Kaida Y, et al. (2013) Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diab Vasc Dis Res 10: 436–441. doi: 10.1177/1479164113486662
[8]
Juni RP, Duckers HJ, Vanhoutte PM, Virmani R, Moens AL (2013) Oxidative stress and pathological changes after coronary artery interventions. J Am Coll Cardiol 61: 1471–1481. doi: 10.1016/j.jacc.2012.11.068
[9]
Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, et al. (2013) Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem 20: 1323–1331. doi: 10.2174/0929867311320100009
[10]
Seet RC, Lee CY, Loke WM, Huang SH, Huang H, et al. (2011) Biomarkers of oxidative damage in cigarette smokers: which biomarkers might reflect acute versus chronic oxidative stress? Free Radic Biol Med 50: 1787–1793. doi: 10.1016/j.freeradbiomed.2011.03.019
[11]
Ganz T (2005) Cellular iron: ferroportin is the only way out. Cell Metab 1: 155–157. doi: 10.1016/j.cmet.2005.02.005
[12]
Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341: 1986–1995. doi: 10.1056/nejm199912233412607
[13]
Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117: 285–297. doi: 10.1016/s0092-8674(04)00343-5
[14]
Fontecave M, Pierre JL (1993) Iron: metabolism, toxicity and therapy. Biochimie 75: 767–773. doi: 10.1016/0300-9084(93)90126-d
[15]
Tang YR, Zhang SQ, Xiong Y, Zhao Y, Fu H, et al. (2003) Studies of five microelement contents in human serum, hair, and fingernails correlated with aged hypertension and coronary heart disease. Biol Trace Elem Res 92: 97–104. doi: 10.1385/bter:92:2:97
[16]
Tremblay AJ, Morrissette H, Gagné JM, Bergeron J, Gagné C, et al. (2004) Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem 37: 785–790. doi: 10.1016/j.clinbiochem.2004.03.008
[17]
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, et al. (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111–1115. doi: 10.1016/0140-6736(92)93147-f
[18]
Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, et al. (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32 Suppl 19–16. doi: 10.1046/j.1365-2362.2002.0320s1009.x
[19]
Ganguli A, Kohli HS, Khullar M, Lal Gupta K, Jha V, et al. (2009) Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail 31: 106–110. doi: 10.1080/08860220802599106
[20]
Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, et al. (2005) Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 68: 2814–2822. doi: 10.1111/j.1523-1755.2005.00754.x
[21]
Bola？os L, González-Juanatey C, Testa A, Ranero R (2008) Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients. Adv Perit Dial 24: 90–95.
[22]
Ozkurt S, Ozenc F, Degirmenci NA, Temiz G, Musmul A, et al. (2012) Acute and sub-acute effects of EV iron sucrose on endothelial functions in haemodialysis patients. Ren Fail 34: 1–6. doi: 10.3109/0886022x.2011.623492
[23]
Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, et al. (2002) Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212–2217. doi: 10.1161/01.cir.0000035250.66458.67
[24]
Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V, et al. (2005) Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 46: 255–264. doi: 10.1536/ihj.46.255
[25]
Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, et al. (2001) Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103: 2799–2804. doi: 10.1161/01.cir.103.23.2799
[26]
Swarnalatha G, Ram R, Neela P, Naidu MU, Dakshina Murty KV (2010) Oxidative stress in haemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl 21: 852–858.
[27]
Poredos P, Jezovnik MK (2013) Testing endothelial function and its clinical relevance. J Atheroscler Thromb 20: 1–8. doi: 10.5551/jat.14340
[28]
Al-Qaisi M, Kharbanda RK, Mittal TK, Donald AE (2008) Measurement of endothelial function and its clinical utility for cardiovascular risk. Vasc Health Risk Manag 4: 647–652.
